Neal is a highly accomplished operator with deep experience in healthcare, IT and big data. Prior to joining Target RWE, Neal served as President and CEO of Symphony Health Solutions, a leading real-world health data, analytics and software which was acquired by PRA Health Sciences in 2017. He assembled and led a team that successfully transformed the business into a high growth technology and data analytics platform.
Prior to Symphony Health, Neal held executive leadership roles at various healthcare solutions businesses, including Focus Diagnostics (Quest Diagnostics) and IMS Health (IQVIA). He attended Dartmouth College and Dartmouth’s Tuck School of Business Administration.
Derek Evans, MBA
Derek Evans is the current President of Target RWE where he oversees product development, engineering, and commercial operations. Derek is an accomplished business professional with more than 25 years of healthcare and software analytics experience. Most recently, Derek was the General Manager of Decision Analytics and Innovation at Change Healthcare, where he was instrumental in the creation and strategy of their healthcare analytics platform.
Prior to Change Healthcare, Mr. Evans served as the SVP and General Manager of Patient Informatics at Symphony Health Solutions, an Icon plc company, where he led the Commercial Effectiveness and Brand Analytics consulting businesses. Over his career, Mr. Evans has worked with his colleagues and clients to develop groundbreaking solutions that have unlocked billions of dollars in incremental revenue. He has focused his expertise on all facets of the healthcare system to bring cohesive, integrated and essential solutions that help improve care delivery.
Derek holds an MBA in marketing and finance from the Fox School of Business at Temple University and a BS in biochemistry and cell biology from Clarkson University.
Michael W. Fried, MD, FAASLD
Co-Founder & Chief Medical Officer
Dr. Fried is Chief Medical Officer and Co-Founder of Target RWE. He is also Professor of Medicine at the University of North Carolina at Chapel Hill and Past-President of the American Association for the Study of Liver Diseases (AASLD). Dr. Fried trained at the State University of New York at Syracuse and the National Institutes of Health, Bethesda, MD, which provided him with the foundation for his 30 years of experience in clinical and translational research. Dr. Fried is co-author of 200+ publications in the field of liver disease and is currently co-chair of the NIH Hepatitis B Research Network. He is co-principal investigator of the HCV-TARGET network which was awarded the FDA Excellence in Regulatory Science Award for contributions to optimizing management for hepatitis C.
Alan Brookhart, PhD
Chief Scientific Officer
Alan is a biostatistician and an epidemiologist who has spent the last 15 years developing and applying epidemiological and statistical methods for studies using real-world healthcare data. He has more than 200 publications in leading journals in medicine, biostatistics, and epidemiology. Alan joined in 2021 when Target RWE acquired his company NoviSci, Inc. At Target RWE, Alan oversees the NoviSci staff and helps catalyze new projects, ideas for analytic software, visualization tools, and research methodology.
Alan is also a Professor in the Department of Population Health Sciences at Duke University, an Adjunct Professor at UNC Chapel Hill, and an Honorary Professor of Clinical Epidemiology at the University of Aarhus, Denmark. Previously Alan was on faculty at Harvard Medical School and was also a co-founder and chair of the scientific advisory board of RxAnte, Inc., a provider of widely used predictive analytics for decision support. Alan is a member of many scientific advisory groups, review panels, and editorial boards.
Chief Data & Analytics Officer
Rob Sullivan joined Target RWE in 2020 to serve as its Chief Data & Analytics Officer, bringing to the team a great deal of experience in the healthcare industry with prior executive level positions at Symphony Health Solutions, Focus Diagnostics (now part of Quest Diagnostics and Eurofins), and IMS Health. In addition, Rob has worked in technical and statistical roles with various pharmaceutical companies in the drug development and commercial phases.
Allison Chandler, JD
Vice President, Compliance and Legal Affairs
Allison joined Target RWE in January 2018 where she previously served as Senior Director of Legal Affairs and is now serving as Vice President, Compliance and Legal Affairs. Her experience includes serving as Assistant General Counsel of the Oklahoma Corporation Commission, various legal consulting roles, and most recently before Target RWE, managing contracts and regulatory operations in site start-up for clinical trials with Syneos Health. Outside of work, Allison enjoys spending time with her husband and three children.
Chief Business Officer
Matt Casbon is currently serving as Chief Business Officer for Target RWE Health Evidence Solutions. Prior to joining Target RWE, Matt was Senior Vice President of Global Strategic Marketing at Circassia where he was responsible for global research sales, global marketing, and training.
Prior to Circassia, Matt worked as the Vice President of Marketing at KemPharm. Matt also previously worked at Chimerix, Salix Pharmaceuticals, Abbott Laboratories, and Solvay Pharmaceuticals in various roles of increasing responsibility. He brings over 25 years of business development, sales and marketing experience, including strategic partnerships, pre-commercial strategy planning, product launches, and sales force operations. Matt received his BA from the West Chester University.
Senior Vice President, Commercial
Brian joins Target RWE after 17+ highly successful years in commercial leadership roles at Symphony Health Solutions where he most recently served as Senior Vice President of Business Development. In this role, Brian led the commercial activities for both the company’s sales and consulting organizations. Prior to leading the commercial team, Brian served as Senior Vice President of Health Data Alliances where he was responsible for data acquisition, supplier relations and industry partnerships.
Brian has additionally held previous leadership roles across various customer segments and geographic territories throughout his career, focusing on sales and business development. Brian received his Bachelor of Business Administration degree from the University of Notre Dame.
Vice President, Technology
Jason Fox is currently serving as Vice President of Technology at Target RWE. Jason has over 15 years’ experience in software engineering and architecture, including stints at NASA’s Jet Propulsion Laboratory and SAS. Jason is an expert in building high performing, highly available software systems for a wide array of industries. Whether it is mission support software for robotic exploration of Mars, or scalable frameworks for high-end analytics, Jason brings his methodical approach and deep understanding of computer systems to solving difficult problems.
Jason received his Master’s degree in Computer Science from Purdue University and his Bachelors in Computer Science Engineering from The Ohio State University.
Vice President, Enterprise Architecture
Viswa has more than 19 years of proven experience spanning analytics, machine learning, application development, and software engineering. Most recently, he served as VP of Architecture and R&D at Symphony Health Solutions where he architected and built various machine learning and analytics toolsets.
In his past experience, Viswa has designed and developed several complex systems including “The (Microbiology) Surveillance Network”, Electronic Lab, and Clinical Analytics Architecture framework. Viswa earned his degree in electrical engineering; however, his professional experience has focused on healthcare and life sciences.
Vice President, Data Operations
Kyle currently serves as Target RWE's vice president of data operations, which he joined in April 2020. Prior to joining Target RWE, Kyle successfully led and transformed the data operations department at Symphony Health Solutions as their Sr. Director of Production Development where he managed the process of onboarding, integrating, and curating different data types and analyses for more than 10+ years.
Joy Peter, RN, BSN
Vice President, Evidence Solutions
Joy Peter is the Vice President of Evidence Solutions at Target RWE. Prior to her current role, Joy served as Associate Director of the HCV-TARGET Network at the University of Florida (UF) where she worked with co-founder Dr. Fried to develop a large international network of 50+ academic and community investigators partnered with the FDA, HCV patient advocacy groups to follow outcomes and rapidly inform clinical practice in patients treated for HCV. Joy helped design several other innovative studies within HCV-TARGET including a large, pragmatic PCORI study, multiple post-marketing commitment and post authorization studies as well as protocols to pair clinical data to biospecimens.
Outside of Target RWE, Joy’s expertise includes more than 20 years of clinical research experience as a nurse with subject matter expertise in liver disease and broad knowledge from her role as Associate Director of Hepatology Clinical Research at UF since 2002.
Meg Powell, PharmD, MBA
Co-Founder & Board Chair
Meg Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. She is currently serving as Board Chair and is the Co-Founder of Target RWE.
Meg has worked with multiple start-up companies while at Medgility, a consulting firm focused on strategy and business development of emerging companies. These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.
Prior to her work at Medgility, Meg was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and global development programs at all stages – from phase 1 to post patent expiry.
Meg received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University.
Eric Edell is Co-Founder and Co-Managing Partner of 22C Capital, a private equity firm committed to delivering capital and critical resources to companies operating at the intersection of technology enablement and data analytics adoption. The Firm has a dedicated focus on the healthcare services, business services, and financial services sectors. 22C's operational and technology resources, including its affiliated data science organization strive to deliver practical, real-world support to help convert these businesses' challenges into opportunities and unlock their full potential.
Mr. Edell received his B.A. in Neuroscience, summa cum laude, from the University of Pennsylvania, where he was a member of Phi Beta Kappa. He lives in Florida with his wife, Deborah, and their three children.
Ryan A. Harris, MD
Ryan Harris, MD brings more than twenty-five years of healthcare experience and fifteen years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, pharma services, healthcare IT, medical devices. Ryan’s current investments include Blue Cloud, Onsite Dental, and Rivermend Health. His previous investments include Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), and iCardiac (acquired by ERT).
Prior to joining Norwest, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused exclusively on healthcare services, pharmaceutical, and medical device investments from large cap buyouts to growth equity and venture.
At Carlyle, Ryan’s deals led to realized profitable exits of more than $2.2 billion equity value. He served as a member or observer on the Board of Directors of Align Technologies (Nasdaq: ALGN), AqueSys, Colin Medical, ConnectiCare, MedPointe Pharmaceuticals, Multiplan, NeoVista, Proteus Biomedical and Qualicaps.
At Industry Ventures, Ryan executed transactions involving Access Closure, Cardiofocus, Ingenuity, and Intarcia. Prior to joining Carlyle in 2002, Ryan was a consultant in the West Coast Healthcare Practice of McKinsey & Company, where he worked with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D and marketing strategies.
Ryan has authored more than 25 peer-reviewed comparative effectiveness articles in publications such as JAMA, Lancet, Annals of Internal Medicine, and the Journal of Health Economics.
Dr. Harris holds an M.D. from the University of California, San Francisco, School of Medicine. In addition, he earned an M.S. in health research and policy, and a B.A. in psychology from Stanford University. Ryan also attended Oxford University’s Magdalen College.
Colleen Coda is a Partner at 22C Capital. Prior to joining 22C, she was Managing Director within Blackstone’s Technology and Innovations group (BXTI). She joined Blackstone in 2011 to build a world class technology organization to drive digital transformation that enabled growth, scale and efficiencies across all aspects of the Firm. While at Blackstone, Colleen held a number of positions, most recently as CTO of several business units including the core Private Equity unit (encompassing seven different investment segments and Portfolio Operations). In addition to her CTO roles, she also oversaw a variety of programs across BXTI including chairing the Diversity and Inclusion Committee, running Product Management and helping run the Technology Innovations Fund which made investments in early stage technology companies. She also led the initiative to consolidate consulting firms into a strategic offshore center that provided services and capabilities across technology, finance and other business functions and grew to over 300 people in India under her leadership.
Colleen was also a member of the Blackstone firmwide Diversity Champion Committee. Prior to joining Blackstone, Colleen was at Capital IQ for 11 years where her last role was Co-CTO focused on Product Development. In this role she was responsible for the strategic product roadmap working across Data & Analytics, Sales, Marketing, and Technology to align the vision of the product all the way through execution. Colleen received her B.S. in Computer Science from Sacred Heart University. She lives in NJ with her husband, Ed, and their three children.
Franz Humer, PhD
Dr. Humer is Chairman of the Board of Directors of the International Centre for Missing & Exploited Children and Chairman of the Humer Foundation. He is also a Non-Executive Director of the Board at Allogene Therapeutics, the Chairman of PCI Services and an Advisor to Temasek Holdings and Letterone Healthcare.
Before joining Roche Group, he was the managing director of Glaxo Pharmaceuticals UK Ltd. and was elected to the Board of Glaxo Holdings plc where he progressed to be responsible for research, business development, manufacturing, commercial strategy, and all non-U.S. operations for 13 years. In 1973, Franz joined Schering-Plough Corporation, where he held various general management positions in Latin America and Europe. In 1995, he joined Hoffmann-La Roche as a member of its Board and the head of its pharmaceuticals division, becoming Chairman and CEO in 2001 and Chairman of Roche Holding Limited between 2008 and 2014. Franz joined the Board of Diageo in 2005, became Chairman in 2008 and retired in 2016. Franz earned a PhD in law from the University of Innsbruck and an MBA from INSEAD in Fontainbleau, France.
Andrew von Eschenbach, MD
Dr. von Eschenbach serves on the Board of Directors of the Reagan-Udall Foundation for the Food and Drug Administration. He is currently President of Samaritan Health Initiatives, a private consulting firm that focuses on improving the ecosystem for the discovery, development, and delivery of innovative 21st century solutions to eliminate disease and restore health, and an Adjunct Professor at the University of Texas UT MD Anderson Cancer Center. In addition, Dr. von Eschenbach is a Senior Fellow and Board member of various research institutions, pharmaceutical and healthcare companies. From 2006 to 2009, Dr. von Eschenbach served as Commissioner of the U.S. Drug and Food Administration, after being appointed Acting Commissioner in 2005. Prior to that, he served as Director of the National Cancer Institute from 2002 to 2006, after spending 26 years at the University of Texas M.D. Anderson Cancer Center, including as Director, Genitourinary Cancer Center.
Dr. von Eschenbach received a B.S. in biology from St. Joseph's University and a MD from Georgetown University School of Medicine.